Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Lease Agreements (Tables)

6 Months Ended

Jun. 30, 2021

The components of our operating lease expense were as follows (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020
Fixed operating lease expense	$	1,340	$	1,340	$	2,680	$	2,680
Variable operating lease expense		163		216		392		467
Total operating lease expense	$	1,503	$	1,556	$	3,072	$	3,147

Supplemental information related to our operating lease were as follow (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020
Cash payments included in the measurement of operating lease liabilities	$	2,529	$	2,432	$	5,025	$	4,832

Supplemental information related to our operating sublease was as follow (in thousands):


		Operating Lease		Sublease Receipts		Net
Remainder of 2021	$	5,057	$	(2,274)	$	2,783
2022		10,485		(4,716)		5,769
2023		877		(394)		483
Total minimum payments required	$	16,419	$	(7,384)	$	9,035